



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Examiner: Misook Yu
Donald L. Durden) Art Unit: 1642
Serial No. 10/770,725) Ref: 1857-ARTI.0024-US-CON-2
Filed: February 3, 2004)
For: "Compositions and Methods)
for Identifying Agents which)
Modulate PTEN Function and PI-3)
Kinase Pathways")

RESPONSE TO ELECTION OF SPECIES REQUIREMENT

The election of species requirement under 35 U.S.C. §121 set forth in the Official Action dated September 27, 2006 has been carefully reviewed. It is noted that a shortened statutory response period of one (1) month was set forth in the September 27, 2006, Official Action. Therefore, the initial due date for response was October 27, 2007. A petition for a four (4) month extension of time is presented with this response, which is being filed within the four (4) month response period.


It is the Examiner's position that the above-identified application contains claims directed to two (2) genres namely the inflammatory diseases encompassed by claim 92 and the immunoreceptor signaling pathways encompassed by claims 97 and 100. Applicant is required to elect a single species for examination purposes.

In response, Applicant hereby elects, without traverse, arthritis as the inflammatory disease, and Fcγ as the immunoreceptor signaling species. Claims 91-101 read on arthritis as the elected species, whereas claims 91-98

and 100-101 read on Fcy as the elected immunoreceptor signaling species.

Early and favorable action on the merits of this application is respectfully solicited.

Respectfully submitted,
DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By 
Kathleen D. Rigaut, Ph.D., J.D.

PTO Registration No. 43,047

Telephone: (215) 563-4100

Facsimile: (215) 563-4044

Email: krigaut@ddhs.com